Proteomic Analysis of Serum in Cardiac Transthyretin Amyloidosis: Diagnostic and Prognostic Implications for Biomarker Discovery
<b>Background/Objectives:</b> Having serum biomarkers available for cardiac transthyretin amyloidosis (ATTR-CA) would be beneficial for diagnosis and prognosis. This study aimed to identify potential ATTR-CA biomarkers through proteomic analysis. <b>Patients and Methods:</b>...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/7/1647 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849770951666827264 |
|---|---|
| author | Joanna Waś Monika Gawor-Prokopczyk Agnieszka Sioma Rafał Szewczyk Aleksandra Pel Jolanta Krzysztoń-Russjan Magdalena Niedolistek Dorota Sokołowska Jacek Grzybowski Łukasz Mazurkiewicz |
| author_facet | Joanna Waś Monika Gawor-Prokopczyk Agnieszka Sioma Rafał Szewczyk Aleksandra Pel Jolanta Krzysztoń-Russjan Magdalena Niedolistek Dorota Sokołowska Jacek Grzybowski Łukasz Mazurkiewicz |
| author_sort | Joanna Waś |
| collection | DOAJ |
| description | <b>Background/Objectives:</b> Having serum biomarkers available for cardiac transthyretin amyloidosis (ATTR-CA) would be beneficial for diagnosis and prognosis. This study aimed to identify potential ATTR-CA biomarkers through proteomic analysis. <b>Patients and Methods:</b> Serum proteomic analyses were conducted on 15 ATTR-CA patients before receiving treatment, 11 ATTR-CA patients who had received tafamidis treatment for at least six months, and 13 patients with suspected cardiac amyloidosis who were later ruled out. All patients underwent blood tests, standard 12-lead electrocardiography, transthoracic echocardiography, and <sup>99m</sup>Tc-DPD scintigraphy. <b>Results:</b> Proteomic analysis revealed significant differences in protein levels among the study groups. Key findings revealed increased levels of several proteins, including ceruloplasmin, apolipoprotein E, SERPINA1, and cDNA FLJ54111 (which is highly similar to serum transferrin), in ATTR-CA patients before receiving specific treatment. There was also a reduction in prothrombin, transferrin, CD14, and alpha-2-macroglobulin. In the ATTR-CA group treated with tafamidis, elevated levels of SERPINA1, paraoxonase 1, and complement C2 were observed. Notably, levels of cDNA FLJ54111 and SERPINA3 were reduced in this group. Compared to the control group, patients with ATTR-CA exhibited higher levels of ceruloplasmin, SERPINA3, and VCAM1, as well as lower levels of ApoA-I, ApoA-II, clusterin, and gelsolin. Controls exhibited elevated levels of transthyretin and prothrombin. <b>Conclusions:</b> This study identified candidate serum biomarkers for diagnosing ATTR-CA and monitoring the effectiveness of tafamidis treatment. |
| format | Article |
| id | doaj-art-4e19a461f33e4e27a2210448b529976e |
| institution | DOAJ |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-4e19a461f33e4e27a2210448b529976e2025-08-20T03:02:48ZengMDPI AGBiomedicines2227-90592025-07-01137164710.3390/biomedicines13071647Proteomic Analysis of Serum in Cardiac Transthyretin Amyloidosis: Diagnostic and Prognostic Implications for Biomarker DiscoveryJoanna Waś0Monika Gawor-Prokopczyk1Agnieszka Sioma2Rafał Szewczyk3Aleksandra Pel4Jolanta Krzysztoń-Russjan5Magdalena Niedolistek6Dorota Sokołowska7Jacek Grzybowski8Łukasz Mazurkiewicz9Department of Medical Biology, National Institute of Cardiology, State Research Institute, 42 Alpejska Str., 04-628 Warsaw, PolandDepartment of Cardiomyopathy, National Institute of Cardiology, State Research Institute, 42 Alpejska Str., 04-628 Warsaw, PolandDepartment of Cardiomyopathy, National Institute of Cardiology, State Research Institute, 42 Alpejska Str., 04-628 Warsaw, PolandLabExperts sp z o.o., 7A Limbowa Str., 80-175 Gdansk, PolandLabExperts sp z o.o., 7A Limbowa Str., 80-175 Gdansk, PolandDepartment of Medical Biology, National Institute of Cardiology, State Research Institute, 42 Alpejska Str., 04-628 Warsaw, PolandDepartment of Medical Biology, National Institute of Cardiology, State Research Institute, 42 Alpejska Str., 04-628 Warsaw, PolandDepartment of Medical Biology, National Institute of Cardiology, State Research Institute, 42 Alpejska Str., 04-628 Warsaw, PolandDepartment of Cardiomyopathy, National Institute of Cardiology, State Research Institute, 42 Alpejska Str., 04-628 Warsaw, PolandDepartment of Cardiomyopathy, National Institute of Cardiology, State Research Institute, 42 Alpejska Str., 04-628 Warsaw, Poland<b>Background/Objectives:</b> Having serum biomarkers available for cardiac transthyretin amyloidosis (ATTR-CA) would be beneficial for diagnosis and prognosis. This study aimed to identify potential ATTR-CA biomarkers through proteomic analysis. <b>Patients and Methods:</b> Serum proteomic analyses were conducted on 15 ATTR-CA patients before receiving treatment, 11 ATTR-CA patients who had received tafamidis treatment for at least six months, and 13 patients with suspected cardiac amyloidosis who were later ruled out. All patients underwent blood tests, standard 12-lead electrocardiography, transthoracic echocardiography, and <sup>99m</sup>Tc-DPD scintigraphy. <b>Results:</b> Proteomic analysis revealed significant differences in protein levels among the study groups. Key findings revealed increased levels of several proteins, including ceruloplasmin, apolipoprotein E, SERPINA1, and cDNA FLJ54111 (which is highly similar to serum transferrin), in ATTR-CA patients before receiving specific treatment. There was also a reduction in prothrombin, transferrin, CD14, and alpha-2-macroglobulin. In the ATTR-CA group treated with tafamidis, elevated levels of SERPINA1, paraoxonase 1, and complement C2 were observed. Notably, levels of cDNA FLJ54111 and SERPINA3 were reduced in this group. Compared to the control group, patients with ATTR-CA exhibited higher levels of ceruloplasmin, SERPINA3, and VCAM1, as well as lower levels of ApoA-I, ApoA-II, clusterin, and gelsolin. Controls exhibited elevated levels of transthyretin and prothrombin. <b>Conclusions:</b> This study identified candidate serum biomarkers for diagnosing ATTR-CA and monitoring the effectiveness of tafamidis treatment.https://www.mdpi.com/2227-9059/13/7/1647transthyretin amyloid cardiomyopathycardiac amyloidosistransthyretintransthyretin amyloidosis |
| spellingShingle | Joanna Waś Monika Gawor-Prokopczyk Agnieszka Sioma Rafał Szewczyk Aleksandra Pel Jolanta Krzysztoń-Russjan Magdalena Niedolistek Dorota Sokołowska Jacek Grzybowski Łukasz Mazurkiewicz Proteomic Analysis of Serum in Cardiac Transthyretin Amyloidosis: Diagnostic and Prognostic Implications for Biomarker Discovery Biomedicines transthyretin amyloid cardiomyopathy cardiac amyloidosis transthyretin transthyretin amyloidosis |
| title | Proteomic Analysis of Serum in Cardiac Transthyretin Amyloidosis: Diagnostic and Prognostic Implications for Biomarker Discovery |
| title_full | Proteomic Analysis of Serum in Cardiac Transthyretin Amyloidosis: Diagnostic and Prognostic Implications for Biomarker Discovery |
| title_fullStr | Proteomic Analysis of Serum in Cardiac Transthyretin Amyloidosis: Diagnostic and Prognostic Implications for Biomarker Discovery |
| title_full_unstemmed | Proteomic Analysis of Serum in Cardiac Transthyretin Amyloidosis: Diagnostic and Prognostic Implications for Biomarker Discovery |
| title_short | Proteomic Analysis of Serum in Cardiac Transthyretin Amyloidosis: Diagnostic and Prognostic Implications for Biomarker Discovery |
| title_sort | proteomic analysis of serum in cardiac transthyretin amyloidosis diagnostic and prognostic implications for biomarker discovery |
| topic | transthyretin amyloid cardiomyopathy cardiac amyloidosis transthyretin transthyretin amyloidosis |
| url | https://www.mdpi.com/2227-9059/13/7/1647 |
| work_keys_str_mv | AT joannawas proteomicanalysisofserumincardiactransthyretinamyloidosisdiagnosticandprognosticimplicationsforbiomarkerdiscovery AT monikagaworprokopczyk proteomicanalysisofserumincardiactransthyretinamyloidosisdiagnosticandprognosticimplicationsforbiomarkerdiscovery AT agnieszkasioma proteomicanalysisofserumincardiactransthyretinamyloidosisdiagnosticandprognosticimplicationsforbiomarkerdiscovery AT rafałszewczyk proteomicanalysisofserumincardiactransthyretinamyloidosisdiagnosticandprognosticimplicationsforbiomarkerdiscovery AT aleksandrapel proteomicanalysisofserumincardiactransthyretinamyloidosisdiagnosticandprognosticimplicationsforbiomarkerdiscovery AT jolantakrzysztonrussjan proteomicanalysisofserumincardiactransthyretinamyloidosisdiagnosticandprognosticimplicationsforbiomarkerdiscovery AT magdalenaniedolistek proteomicanalysisofserumincardiactransthyretinamyloidosisdiagnosticandprognosticimplicationsforbiomarkerdiscovery AT dorotasokołowska proteomicanalysisofserumincardiactransthyretinamyloidosisdiagnosticandprognosticimplicationsforbiomarkerdiscovery AT jacekgrzybowski proteomicanalysisofserumincardiactransthyretinamyloidosisdiagnosticandprognosticimplicationsforbiomarkerdiscovery AT łukaszmazurkiewicz proteomicanalysisofserumincardiactransthyretinamyloidosisdiagnosticandprognosticimplicationsforbiomarkerdiscovery |